Who
Forbion Growth Opportunities Fund III Cooperatief U.A.
10% owner
Company insider
Files Form 4 as: 10% owner, Braveheart Bio.
In numbers
- Trades disclosed
- 12
- Buys
- 1
- Sells
- 0
- Bought
- $129.6M
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 7 Aug 2026
- Last trade
- 7 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Code C | —9,132,420 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Code C | —7,990,867 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Bought | $34.6M1,920,000 at $18.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart Biooption or derivative · Biotechnology | SEC FORM 4 Code C | —40,000,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart Biooption or derivative · Biotechnology | SEC FORM 4 Code C | —35,000,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Bought | $30.2M1,680,000 at $18.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart Biooption or derivative · Biotechnology | SEC FORM 4 Code C | —40,000,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart Biooption or derivative · Biotechnology | SEC FORM 4 Code C | —35,000,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Code C | —9,132,420 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Code C | —7,990,867 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Bought | $34.6M1,920,000 at $18.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Bought | $30.2M1,680,000 at $18.00 | filing |
News
No headline names them, or the companies they trade most, lately.